TMTiago Moreira

Tiago Moreira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tiago Moreira has a total of 524 co-authors. Here are the top co-authors by number of shared publications:

  • Niaz Ahmed

    Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

    7 shared publications
  • Hany Aref

    Ain Shams University, Cairo, Egypt

    3 shared publications
  • Michael V. Mazya

    From the Department of Neurology (T.N.N., P.K., Anvitha Sathya, H.C.L., Andreas Charidimou, Judith Clark, S.K.F., J.R.R.), Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine; Department of Radiology (T.N.N., M.M.Q., P.K., Mohamad Abdalkader, Anvitha Sathya, H.C.L., N.L.K.), Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine; Department of Radiation Oncology (M.M.Q.), Boston Medical Center, Boston University Chobanian &...

    3 shared publications
  • Michael V. Mazya

    Department of Neurology, Karolinska University Hospital, Stockholm, Sweden 25

    3 shared publications
  • Nadim Anani

    Health Informatics Centre, LIME, Karolinska Institutet, Stockholm, Sweden

    3 shared publications
  • Sabine Koch

    Health Informatics Centre, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden

    3 shared publications

Latest Publications

  • Safety and Outcomes of Dabigatran Reversal With Idarucizumab Before IV Thrombolysis in Patients With Acute Ischemic Stroke

    by Malin Säflund, Marius Matusevicius, Georgios Tsivgoulis, Alberto Chiti, Senta Frol, Argyro Kiamili, André Peeters, Marco Petruzzellis, Eugenia Rota, Danilo Toni, et al.

    IV thrombolysis (IVT) is contraindicated in patients with acute ischemic stroke (AIS) while on dabigatran or other oral anticoagulant (OAC) treatment. Idarucizumab completely reverses the effect of dabigatran within minutes, without increasing the risk of thromboembolism. Limited data exist on IVT treatment after dabigatran reversal with idarucizumab. We aimed to investigate the safety and outcomes of IVT after dabigatran reversal in patients with AIS. This is an observational study based on the Safe Implementation of Treatment in Stroke (SITS) International Stroke Thrombolysis Registry. Hospitals treating patients with AIS contributed data. The main outcome was safety as measured by any parenchymal hematoma (PH), symptomatic intracerebral hemorrhage (SICH) per SITS, and death within 3 months. The secondary outcome was functional independence defined as modified Rankin Scale scores of 0-2 at 3 months. Propensity score matching (PSM) was used to compare patients treated with dabigatran reversal to patients without prior OAC in primary analysis and for secondary analysis between patients treated with dabigatran reversal with idarucizumab to patients on dabigatran without reversal treatment. Among 258,589 IVT treated patients with AIS, 510 were on dabigatran and 156 received dabigatran reversal. Dabigatran reversal patients were older (75 vs 69 years, p < 0.01), had similar median baseline NIH Stroke Scale (9 vs 10, p = 0.47), and longer onset to IVT time (185 vs 150 minutes, p < 0.01) compared with patients without prior OAC treatment (n = 191,648). After PSM analysis where good balance was achieved, patients treated with dabigatran reversal before IVT had similar results in all outcomes as compared with patients treated with IVT without prior OAC (any PH: 3 vs 9%, p = 0.10; SICH: 1 vs 1%, p = 1.00; death: 25 vs 19%, p = 0.33, functional independence: 51 vs 52%, p = 0.95). Secondary analysis showed similar results for all outcomes before and after PSM. In our observational study with patients with AIS, IVT treatment after dabigatran reversal was safe and had similar outcomes to IVT treatment without previous OAC. Furthermore, comparison between dabigatran reversal vs no reversal also indicates that IVT is safe for patients on dabigatran without idarucizumab reversal, which is currently being investigated in clinical trials. This study provides Class III evidence that IVT after idarucizumab reversal in patients with AIS who took dabigatran within 48 hours of onset of symptoms is safe and comparable with those of patients with AIS not on prior oral anticoagulation.


  • Open Access

    Intravenous Thrombolysis for Acute Ischemic Stroke Across the Middle East and North Africa (2021–2023): Results from the SITS-MENA Registry

    by Maria Khan, Marius Matusevicius, Suhail AlRukn, Abdoreza Ghoreishi, Mehdi Farhoudi, Elyar Sadeghi Hokmabadi, Payam Sariaslani, Tamer Roushdy, Naveed Akhtar, Yahia Imam, et al.

    Background: Intravenous thrombolysis (IVT) for acute ischemic stroke in the Middle-East and North African (MENA) countries has increased in the last decade, but long-term outcomes and quality of care are less well studied. Methods: This was a prospective observational study to examine 3-month outcomes of IVT-treated patients in MENA stroke units using the SITS Registry. Findings: There were 2768 patients in MENA and 7163 patents in non-MENA treated with IVT and registered in SITS between August 2021 and September 2023. Compared to non-MENA, MENA patients were younger (65 vs 72 years-old), had higher NIH Stroke Scale scores at baseline (11 vs 9) and shorter door-to-needle times (30 vs 54 min). The most common risk factors in MENA were hypertension (64.9 vs 69.8 %) and diabetes (30.8 vs 20.1%). Functional independence at 3 months was similar (56.6% vs 57.7%); however, mortality at 7 and 30 days was significantly higher in MENA (8.3% vs 5.3% and 20.7 vs 14.5%). Symptomatic intracranial hemorrhage rates were low in both groups (<1.2% per SITS-MOST). Early mortality rates related to stroke were comparable (56.7 vs 59.2%) but early deaths caused by myocardial infarction, pneumonia, pulmonary embolism and sepsis were more frequent in MENA (14.2 vs 4.6%, 6.7 vs 4.6%, 1.5 vs 0.4% and 3 vs 1.8%). Interpretation: The overall mortality of IVT-treated patients was increased in MENA at 7 and 90 days post-stroke. Differences in risk factors at baseline may account for mortality but the treatment of medical complications in MENA stroke units warrants further study.

  • Endovascular thrombectomy in addition to intravenous thrombolysis versus intravenous thrombolysis alone in medium distal vessel occlusions: Results from the SITS International Stroke Treatment Register

    by Boris Keselman, Michael V Mazya, Daniel Strbian, Ana Paiva Nunes, Andrea Naldi, Danilo Toni, Marco Petruzzellis, Giovanni Frisullo, Dalius Jatuzis, Silvia Strumia, et al.

    Background: Endovascular thrombectomy (EVT) is the standard of care for large-vessel occlusion stroke. Medium distal vessel occlusions (MDVO) account for 25–40% of acute ischemic stroke cases, but recanalization rates with intravenous thrombolysis (IVT) are often less than 50%. Recent randomized trials have failed to show better outcomes after EVT versus best medical management in MDVO stroke. The main research question of the study: Is the addition of EVT to IVT associated with benefits or harm when treating patients with MDVO stroke? Methods: We performed a retrospective observational study of patients in the Safe Implementation of Treatments of Stroke International Stroke Treatment Registry (SITS-ISTR) 2016–2023, treated with IVT or IVT + EVT for occlusion of the anterior cerebral artery (ACA), posterior cerebral artery (PCA) or distal middle cerebral artery (MCA; M3 and more distal). Only patients with available occlusion data from computed tomographic angiography (CTA) or magnetic resonance angiography (MRA) were included. Patients with M2 occlusions or those treated with EVT only were excluded. Outcomes were acute post-treatment hemorrhage, 3-month modified Rankin Scale (mRS) score, and death at 3 months. Propensity score matching was performed due to baseline imbalances (age, National Institutes of Health Stroke Scale [NIHSS], and occlusion site). Results: Of 2198 included patients, 295 (13%) were treated with IVT + EVT, and 1903 (87%) received IVT alone. IVT + EVT patients were younger (73 vs. 75) and had higher median NIHSS: 10 (interquartile range [IQR]: 6–15) versus 8 (5–12), p < 0.001. More IVT + EVT patients were functionally independent (mRS 0-1) before stroke at 91.8% versus 83.0% (p < 0.001). For the IVT + EVT group, PCA occlusion was the most common (n = 179, 60.7%), and distal MCA (n = 1140, 59.9%) in the IVT group. After propensity score matching, IVT + EVT was associated with worse 3-month outcomes compared to IVT alone: mRS 0-1 (35.8% vs. 47.0%, p = 0.016, mRS 0-2 52.4% vs. 63.4%, p = 0.017, and death 21.4% vs. 11.8%, p = 0.005). Symptomatic intracerebral hemorrhage rates were higher in the IVT + EVT group according to European Collaborative Stroke Study II (ECASS II): 6.5% versus 2.4%, p = 0.043, but were similar according to National Institute of Neurological Disorders and Stroke (NINDS): 8.2% versus 4.2%, p = 0.095, and Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST): 0.6% versus 1.2%, p = 0.825. Conclusions: IVT + EVT for MDVO was associated with worse functional outcomes compared to IVT alone. Our results support recent publications but should be interpreted with caution due to the retrospective observational design, warranting further RCTs.


  • Open Access

    Paroxysmal tilt illusion after blinking—an unusual form of stroke manifesting with parietal vertigo

    by Cecilia Ronnevi, Tiago Moreira

    A man in his 70s had an episode of vertical visual tilt after blinking, as if the room tilted to the right, and of deviation of the body to the right when he walked, together with slight vertigo and nausea. He was initially suspected to have a transient ischaemic attack and was investigated with neuroradiology, telemetry and echocardiography. Neurological examination showed horizontal saccadic eye movements and deviation to the right with the Unterberger’s test. Brain MRI revealed a minor stroke in the right parieto-occipital junction and an older, smaller infarction in the right cerebellum. There was only slight intimal atherosclerosis, and no cardiac abnormality was found. The stroke was classified as an embolic stroke of undetermined source. Distinguishing central from peripheral lesions when symptoms are transient and discrete is challenging. Emergent brain MRI in patients with subtle subjective visual vertical tilt and vertigo can identify acute parieto-insular ischaemia.

  • Open Access

    Thrombectomy in addition to thrombolysis for medium distal vessel occlusions - results from the SITS registry

    by Boris Keselman, Michael Mazya, Daniel Strbian, Ana Paiva Nunes, Andrea Naldi, Danilo Toni, Marco Petruzzellis, Giovanni Frisullo, Dalius Jatuzis, Silvia Strumia, et al.

    Background Endovascular thrombectomy (EVT) is standard of care for acute ischemic stroke (AIS) caused by large vessel occlusion. Medium distal vessel occlusions (MDVO) account for 25-40% AIS cases, but recanalization rates with intravenous thrombolysis (IVT) are often below 50%. Studies have shown mixed results comparing EVT with best medical management in different MDVO populations. This study aims to show if EVT in addition to IVT is associated with clinical benefits or harm in patients with MDVO. Methods We performed an observational study of patients in the Safe Implementation of Treatments of Stroke International Stroke Registry (SITS-ISTR) 2016–23, treated with IVT or IVT+EVT for occlusion of the ACA, PCA or distal MCA (M3 and more distal). Outcomes were modified Rankin Scale score (mRS), death at 3 months, and post-treatment hemorrhage. Inverse probability treatment weighting and binomial logistic regression was performed due to baseline imbalances (age, NIHSS and occlusion site). Results Of 2198 included patients, 1903 (87%) received IVT, and 295 (13%) IVT+EVT. IVT+EVT patients were younger (73 vs 75) and had higher median NIHSS: 10 (IQR 6-15) vs 8 (5-12), pConclusions IVT+EVT for MDVO was associated with worse outcomes compared to IVT alone. Results should be interpreted with caution due to retrospective observational design, warranting further randomized studies, but are in line with recently published RCTs

  • Open Access

    Timing of Antithrombotic Secondary Prevention in Patients with Intracranial Hemorrhage after Stroke Thrombolysis and Thrombectomy

    by Giuseppe Reale, Pietro Caliandro, Tiago T. P. Moreira, Håkan Almqvist, Silvia Giovannini, David Grannas, Maria Ioanna Kotopouli, Andrea Laurienzo, Harald Löfberg, Marco Moci, et al.

    In patients with acute ischemic stroke, hemorrhagic transformation (HT) of infarcted tissue frequently occurs after reperfusion treatment. We aimed to assess whether HT and its severity influences the start of secondary prevention therapy and increases the risk of stroke recurrence. In this retrospective dual-center study, we recruited ischemic stroke patients treated with thrombolysis, thrombectomy or both. Our primary outcome was the time between revascularization and the start of any secondary prevention therapy. The secondary outcome was ischemic stroke recurrence within three months. We compared patients with vs. without HT and no (n = 653), minor (n = 158) and major (n = 51) HT patients using propensity score matching. The delay in the start of antithrombotics or anticoagulants was median 24 h in no HT, 26 h in minor HT and 39 h in major HT. No and minor HT patients had similar rates of any stroke recurrence (3.4% (all ischemic) vs. 2.5% (1.6% ischemic plus 0.9% hemorrhagic)). Major HT patients had a higher stroke recurrence at 7.8% (3.9% ischemic, 3.9% hemorrhagic), but this difference did not reach significance. A total of 22% of major HT patients did not start any antithrombotic treatment during the three-month follow-up. In conclusion, the presence of HT influences the timing of secondary prevention in ischemic stroke patients undergoing reperfusion treatments. Minor HT did not delay the start of antithrombotics or anticoagulants compared to no HT, with no significant difference in safety outcomes. Major HT patients remain a clinical challenge with both a delayed or lacking start of treatment. In this group, we did not see a higher rate of ischemic recurrence; however, this may have been censored by elevated early mortality. While not reaching statistical significance, hemorrhagic recurrence was somewhat more common in this group, warranting further study using larger datasets.


  • Global Impact of the COVID-19 Pandemic on Stroke Volumes and Cerebrovascular Events

    by Thanh N. Nguyen, Muhammad M. Qureshi, Piers Klein, Hiroshi Yamagami, Robert Mikulik, Anna Czlonkowska, Mohamad Abdalkader, Petra Sedova, Anvitha Sathya, Hannah C. Lo, et al.

    Background and Objectives Declines in stroke admission, IV thrombolysis (IVT), and mechanical thrombectomy volumes were reported during the first wave of the COVID-19 pandemic. There is a paucity of data on the longer-term effect of the pandemic on stroke volumes over the course of a year and through the second wave of the pandemic. We sought to measure the effect of the COVID-19 pandemic on the volumes of stroke admissions, intracranial hemorrhage (ICH), IVT, and mechanical thrombectomy over a 1-year period at the onset of the pandemic (March 1, 2020, to February 28, 2021) compared with the immediately preceding year (March 1, 2019, to February 29, 2020). Methods We conducted a longitudinal retrospective study across 6 continents, 56 countries, and 275 stroke centers. We collected volume data for COVID-19 admissions and 4 stroke metrics: ischemic stroke admissions, ICH admissions, IVT treatments, and mechanical thrombectomy procedures. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases. Results There were 148,895 stroke admissions in the 1 year immediately before compared with 138,453 admissions during the 1-year pandemic, representing a 7% decline (95% CI [95% CI 7.1–6.9]; p < 0.0001). ICH volumes declined from 29,585 to 28,156 (4.8% [5.1–4.6]; p < 0.0001) and IVT volume from 24,584 to 23,077 (6.1% [6.4–5.8]; p < 0.0001). Larger declines were observed at high-volume compared with low-volume centers (all p < 0.0001). There was no significant change in mechanical thrombectomy volumes (0.7% [0.6–0.9]; p = 0.49). Stroke was diagnosed in 1.3% [1.31–1.38] of 406,792 COVID-19 hospitalizations. SARS-CoV-2 infection was present in 2.9% ([2.82–2.97], 5,656/195,539) of all stroke hospitalizations. Discussion There was a global decline and shift to lower-volume centers of stroke admission volumes, ICH volumes, and IVT volumes during the 1st year of the COVID-19 pandemic compared with the prior year. Mechanical thrombectomy volumes were preserved. These results suggest preservation in the stroke care of higher severity of disease through the first pandemic year. Trial Registration Information This study is registered under NCT04934020.


  • Open Access

    Staff and Facility Utilization in Direct Patient Transfer to the Comprehensive Stroke Center: Testing a Real-Time Location System for Automatic Patient Pathway Characterization

    by Tiago Moreira, Alexander Furnica, Elke Daemen, Michael V. Mazya, Christina Sjöstrand, Magnus Kaijser, Evert van Loenen

    Introduction: Starting reperfusion therapies as early as possible in acute ischemic strokes are of utmost importance to improve outcomes. The Comprehensive Stroke Centers (CSCs) can use surveys, shadowing personnel or perform journal analysis to improve logistics, which can be labor intensive, lack accuracy, and disturb the staff by requiring manual intervention. The aim of this study was to measure transport times, facility usage, and patient–staff colocalization with an automated real-time location system (RTLS).Patients and Methods: We tested IR detection of patient wristbands and staff badges in parallel with a period when the triage of stroke patients was changed from admission to the emergency room (ER) to direct admission to neuroradiology.Results: In total, 281 patients were enrolled. In 242/281 (86%) of cases, stroke patient logistics could be detected. Consistent patient–staff colocalizations were detected in 177/281 (63%) of cases. Bypassing the ER led to a significant decrease in median time neurologists spent with patients (from 15 to 9 min), but to an increase of the time nurses spent with patients (from 13 to 22 min; p = 0.036). Ischemic stroke patients used the most staff time (median 25 min) compared to hemorrhagic stroke patients (median 13 min) and stroke mimics (median 15 min).Discussion: Time spent with patients increased for nurses, but decreased for neurologists after direct triage to the CSC. While lower in-hospital transport times were detected, time spent in neuroradiology (CT room and waiting) remained unchanged.Conclusion: The RTLS could be used to measure the timestamps in stroke pathways and assist in staff allocation.


  • Open Access

    Novel Mutation of the TGF-β 3 Protein (Loeys-Dietz Type 5) Associated With Aortic and Carotid Dissections

    by Dargham Hussein, Christian Olsson, Kristina Lagerstedt-Robinson, Tiago Moreira

    Objectives Loeys-Dietz syndrome (LDS) is a rare genetic cause of stroke associated with connective tissue disorders but is not well known among stroke physicians.1 The main objectives of this case report are to increase awareness of this condition and to improve stroke prevention at follow-up visits. Methods A patient with aortic and carotid artery dissection who had undergone 2 major aortic surgeries with mechanical composite graft and treated with full-dose anticoagulation was reevaluated by neurologists due to retinal hypoperfusion symptoms. After musculoskeletal examination, cervical ultrasonography, and computerized tomography angiography, he was referred for whole-genome sequencing. Results We found joint hypermobility, skin hyperelasticity, bifid uvula, and combined cervical artery dissections that caused intermittently decreased blood flow in the left ophthalmic artery and an acute asymptomatic embolic stroke. A novel pathogenic variant of LDS type 5 consisting of a heterogeneous nonsense variant c.1044C>A, p.(Cys384*) was found in the TGF-β 3 (TGFB3) gene. Consequently, anticoagulation was intensified, and at 1-year follow-up, the patient9s symptoms improved. Discussion This novel genetic variant coupled to the patient9s phenotype contributes to the knowledge of genetic causes of stroke. Patients with multiple arterial dissections and musculoskeletal features should be offered genetic testing and be carefully evaluated to avoid further cerebrovascular ischemic lesions.


  • Changing the face of stroke care in the Middle East North Africa region

    by Maria Khan, Suhail Al-Rukn, Adel Ali Alhazzani, Hany Aref, Tiago Moreira, Nils Wahlgren